ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: TH-PO975

Efficacy and Safety of Roxadustat in Peritoneal Dialysis CKD: Pooled Analysis of Four Phase 3 Studies

Session Information

Category: Dialysis

  • 701 Dialysis: Hemodialysis and Frequent Dialysis

Authors

  • Fliser, Danilo, Saarland University Medical Center and Saarland University, Homburg, Germany
  • Bhandari, Sunil, Hull University Teaching Hospitals NHS Trust and Hull York Medical School, York, United Kingdom
  • Ortiz, Alberto, Fundacion Jimenez Diaz, Madrid, Spain
  • Santos, Vicki R., Astellas Pharma US Inc, Northbrook, Illinois, United States
  • Jiletcovici, Alina, Astellas Pharma US Inc, Northbrook, Illinois, United States
  • Akizawa, Tadao, Showa University School of Medicine, Tokyo, Japan
Background

Roxadustat is an oral HIF-PH inhibitor for anemia of CKD treatment. This pooled subgroup analysis examined the efficacy, need for transfusions, and safety of roxadustat compared with ESA in patients with anemia of CKD on peritoneal dialysis (PD) from the ALPINE studies, a large global phase 3 program.

Methods

Data from four multicenter, randomized, open-label studies comparing roxadustat to ESAs (epoetin alfa or darbepoetin alfa) in patients on PD were included in this pooled analysis (PYRENEES, SIERRAS, HIMALAYAS, ROCKIES). Hb target (g/dL) for roxadustat in all studies was 10.0-12.0, and ESA use followed local guidelines and labeling. Endpoints evaluated were Hb change from baseline to Weeks 28-36 (without rescue therapy, ie, RBC transfusion and/or ESA use), Hb change from baseline to Weeks 28-52 (regardless of rescue therapy), and time to rescue therapy. Safety and tolerability were assessed by treatment-emergent adverse events (TEAEs) from first study drug administration up to 28 days after the last dose. Nominal P-values are reported.

Results

In total, 422 patients were included (215 roxadustat, 207 ESA). Mean (SD) baseline Hb (g/dL) was 9.8 (1.2) for patients treated with roxadustat and 9.7 (1.2) for patients treated with ESA. Patients treated with roxadustat achieved a larger least-squares mean (LSM) change from baseline to Weeks 28-36 in Hb without rescue therapy versus ESA (roxadustat LSM: 1.38; 95% CI: 1.21-1.56; ESA LSM: 0.97; 95% CI: 0.78-1.16; LSM difference: 0.41; 95% CI: 0.16-0.67; P=0.0017) and Hb change from baseline to Weeks 28-52 regardless of rescue therapy (roxadustat LSM: 1.31; 95% CI: 1.15-1.47; ESA LSM: 1.00; 95% CI: 0.82-1.17; LSM difference: 0.32; 95% CI: 0.08-0.55; P=0.0077). Risk for RBC transfusion was reduced for patients treated with roxadustat versus ESA (HR: 0.49; 95% CI: 0.25-0.93; P=0.0304). The incidence rates per 100 patient-exposure years for overall TEAEs (56.5 vs 54.4), grade ≥3 TEAEs (27.7 vs 27.5), and serious TEAEs (37.2 vs 35.8) were similar in the roxadustat and the ESA treatment groups, respectively.

Conclusion

This pooled analysis demonstrates that roxadustat, an oral medication, corrected and maintained Hb levels in patients with anemia of CKD on PD similarly to ESAs with a comparable safety profile.

Funding

  • Commercial Support – Astellas Pharma, Inc., FibroGen, Inc., AstraZeneca